Evelo Biosciences, Inc. (EVLO) Event May 12, 2022, 00:00 UTC (51% Neutral) Evelo Biosciences, Inc. (EVLO) Reports Net Loss for 2022-03-31 Full text
Register to leave comments News bot Oct. 29, 2025, 8:48 a.m. 🏢 Evelo Biosciences, Inc. (EVLO) - Form 10-Q Quarterly Report Quarterly financial filing submitted to the SEC 📋 Filing Information 📄 Form Type: 10-Q 📅 Filing Date: 2022-05-12 📊 Period of Report: 2022-03-31 ⏰ Accepted: N/A 📊 Key Financial Metrics (Period-over-Period Comparison) Metric Current Period Previous Period Change ($) Change (%) Trend Net Income/Loss $-28.20M $-28.20M N/A +0.00% ➡️ Total Assets $87.87M $58.83M $29.05M +49.38% 📈 Total Liabilities $79.20M $75.63M $3.58M +4.73% ↗️ Stockholders' Equity $87.84M $-320.71M $408.55M +127.39% 📈 Operating Income/Loss $-27.47M $-28.74M $1.27M +4.41% ↗️ R&D Expense $21.51M $19.32M $2.19M +11.32% 📉 Cash $1.45M $5.22M $-3.77M -72.21% 📉 Earningspersharebasic $-0.55 $-0.56 $0.01 +1.79% ➡️ Earningspersharediluted $-0.55 $-0.56 $0.01 +1.79% ➡️ 📈 Financial Trend Analysis 🔻 Reported net loss for the period • 🏦 Strengthened balance sheet with assets growing faster than liabilities 📎 View Full 10-Q Filing on SEC.gov Access the complete official filing document
🏢 Evelo Biosciences, Inc. (EVLO) - Form 10-Q Quarterly Report
📋 Filing Information
Key Financial Metrics (Period-over-Period Comparison)
Financial Trend Analysis
🔻 Reported net loss for the period • 🏦 Strengthened balance sheet with assets growing faster than liabilities
📎 View Full 10-Q Filing on SEC.gov
Access the complete official filing document